Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT)

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Detemir, published as a randomized controlled trial.

The purpose of this study was to compare effects of insulin detemir once daily versus twice a day in a basal-bolus insulin regimen.

Who Took Part

The abstract describes 520 patients taking part.

In this open-label, 7-month study, 520 patients with type 1 diabetes were randomly assigned to receive detemir once daily or twice daily with mealtime insulin aspart.

Thereafter, patients were able to switch from one regimen to the other, with an additional nonrandomized 3-month follow-up, to a total of 7 months.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Everyone knew when Insulin Aspart was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Eating, Glycated Hemoglobin, Insulin Aspart, Insulin Detemir and Insulin, Long-Acting.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and Insulin Detemir in 520 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.